Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer

Journal of Clinical Oncology

Volumn 26, Issue 11, 2008, Pages 1830-1835

  Gruenberger, Brigit ^a   Tamandl, Dietmar ^a   Schueller, Johannes ^a   Scheithauer, Werner ^a   Zielinski, Christoph ^a   Herbst, Friedrich ^a   Gruenberger, Thomas ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; OXALIPLATIN; UNCLASSIFIED DRUG; XELOX; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RISK; CANCER SURGERY; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; FEMALE; HAND FOOT SYNDROME; HEMATOLOGIC DISEASE; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; LIVER FUNCTION; LIVER METASTASIS; LIVER REGENERATION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; SEPSIS; SMALL INTESTINE DISEASE; THROMBOEMBOLISM; TREATMENT OUTCOME; URINARY TRACT INFECTION; WOUND INFECTION; ADJUVANT CHEMOTHERAPY; CHEMICALLY INDUCED DISORDER; COLORECTAL TUMOR; DRUG ADMINISTRATION; DRUG EFFECT; INTRAVENOUS DRUG ADMINISTRATION; LIVER TUMOR; METASTASIS; MIDDLE AGED; PATHOLOGY; SURVIVAL RATE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DIARRHEA; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HEMATOLOGIC DISEASES; HUMANS; INFUSIONS, INTRAVENOUS; LIVER NEOPLASMS; LIVER REGENERATION; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PERIPHERAL NERVOUS SYSTEM DISEASES; SURVIVAL RATE;

EID: 42949130734     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.13.7679     Document Type: Article

References (31)

1. Boyle P, Leon ME: Epidemiology of colorectal cancer. Br Med Bull 64:1-25, 2002
2. Scheithauer W, Rosen H, Kornek GV, et al: Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 306:752-755, 1993
3. Douillard J, Cunningham G, Roth A, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355:1041-1047, 2000
4. Colucci G, Gebbia V, Paoletti G, et al: Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: A multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 23:4866-4875, 2005
5. Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30, 2004
6. Grothey A, Sargent D, Goldberg RM, et al: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracilleucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22:1209-1214, 2004
7. Falcone A, Ricci S, Brunetti I, et al: Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: The Gruppo Oncologico Nord Ovest. J Clin Oncol 25:1670-1676, 2007
8. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for the treatment of metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
9. Kabbinavar FF, Schulz J, McCleod M, et al: Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. J Clin Oncol 23:3697-3705, 2005
10. Saltz L, Clarke S, Díaz-Rubio E, et al: Updated efficacy results from XELOX-1/NO16966, a randomised phase III trial in first-line metastatic colorectal cancer: Analysis of bevacizumab in combination with XELOX or FOLFOX-4. Ann Oncol 18:vii21, 2007 (suppl 7; abstr O-0032)
11. Adam R: Chemotherapy and surgery: New perspectives on the treatment of unresectable liver metastases. Ann Oncol 14:ii13-ii16, 2003 (suppl 2)
12. Van Cutsem E, Nordlinger B, Adam R, et al: Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 42:2212-2221, 2006
13. Choti MA, Sitzmann JV, Tiburi MF, et al: Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 235:759-766, 2002
14. Fong Y, Cohen AM, Fortner JG, et al: Liver resection for colorectal metastases. J Clin Oncol 15:938-946, 1999
15. Fong Y, Fortner J, Sun RL, et al: Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases. Ann Surg 230:309-318, 1999
16. Chong G, Cunningham D: Improving long-term outcomes for patients with liver metastases from colorectal cancer. J Clin Oncol 23:9063-9066, 2005
17. Ellis LM, Curley SA, Grothey A: Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. J Clin Oncol 23:4853-4855, 2005
18. Leichman L: Neoadjuvant chemotherapy for disseminated colorectal cancer: Changing the paradigm. J Clin Oncol 24:3817-3818, 2006
19. Nordlinger B, Van Cutsem E, Rougier P, et al: Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. Eur J Cancer 43:2037-2045, 2007
20. Nordlinger B, Sorbye H, Collette L, et al: Final results of the EORTC Intergroup randomized phase III study 40983 [EPOC] evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases. J Clin Oncol 25:2s, 2007 (suppl; abstr LBA5)
21. Tobelem G: VEGF: A key therapeutic target for the treatment of cancer-insights into its role and pharmacological inhibition. Targeted Oncology 2:153-164, 2007
22. MacDonald J, Haller D, Mayer R: Grading of toxicity, in MacDonald J, Haller D, Mayer R (eds): Manual of Oncologic Therapeutics. Philadelphia, PA, Lippincott, 1995, pp 519-523
23. Karoui M, Penna C, Amin-Hashem M, et al: Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 243:1-7, 2006
24. Tamandl D, Gruenberger B, Herberger B, et al: Selective resection of colorectal liver metastases. Eur J Surg Oncol 33:174-182, 2007
25. Berry S, Cunningham D, Michael M, et al: Preliminary efficacy of bevacizumab with first-line FOLFOX, XELOX, FOLFIRI and fluoropyrimidines for mCRC: First BEAT. Eur J Cancer Suppl 5:241, 2007 (abstr 3020)
26. Rivera F, Van Cutsem E, Kretzschmar A, et al: Preliminary efficacy of bevacizumab with first-line FOLFOX, XELOX, FOLFIRI and monotherapy for mCRC: First BEATrial. Ann Oncol 18:vii19, 2007 (suppl; abstr O-0025)
27. Hochster HS, Hart L, Ramanathan RK, et al: Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): final analysis of the TREE Study. J Clin Oncol 24:148s, 2006 (suppl; abstr 3510)
28. Bendell JC, Fernando N, Morse M, et al: A phase II study of oxaliplatin (OX), capecitabine (CAP), and bevacizumab (BV) in the treatment of metastatic colorectal cancer. J Clin Oncol 24:156s, 2006 (suppl; abstr 3541)
29. Kesmodel SB, Ellis LM, Lin E, et al: Complication rates following hepatic surgery in patients receiving neoadjuvant bevacizumab for colorectal cancer liver metastases. Presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium, Orlando, FL, January 19-21 2007
30. Roche: Bevacizumab (Avastin) Summary of Product Characteristics. http://www.roche.com
31. Nordlinger B, Benoist S: Benefits and risks of neoadjuvant therapy for liver metastases. J Clin Oncol 24:4954-4955, 2006